



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Review Paper

Development of a critical appraisal tool for models predicting the impact of ‘test, trace, and protect’ programmes on COVID-19 transmission

J.W. Frank^{a,*}, G. Marion^b, A. Doeschl-Wilson^c

^a Usher Institute, University of Edinburgh, Teviot Hall, Edinburgh EH8 9DX, Scotland, UK

^b Biomathematics and Statistics Scotland, James Clerk Maxwell Building, Edinburgh EH9 3FD, Scotland, UK

^c The Roslin Institute, University of Edinburgh, Roslin Institute Building, Easter Bush EH25 9RG, Scotland, UK

ARTICLE INFO

Article history:

Received 17 May 2021

Received in revised form

1 October 2021

Accepted 8 October 2021

Available online 18 October 2021

Keywords:

COVID-19

Disease transmission

Mathematical model(s)

Test and trace

Evaluation of contact tracing

Critical appraisal

ABSTRACT

Objectives: To develop a critical appraisal tool for non-computational-specialist public health professionals to assess the quality and relevance of modelling studies about Test and Trace (and Protect – TTP) programmes' impact on COVID-19 transmission.

Study design: Decision-making tool development.

Methods: Using Tugwell et al.'s 1985 Health Care Effectiveness equation as a conceptual framework, combined with a purposive search of the relevant early modeling literature, we developed six critical appraisal questions for the rapid assessment of modeling studies related to the evaluation of TTP programmes' effectiveness.

Results: By applying the critical appraisal tool to selected recent COVID-19 modeling studies, we demonstrate how models can be evaluated using the six questions to evaluate internal and external validity and relevance.

Conclusions: These six critical appraisal questions are able to discriminate between modeling studies of higher and lower quality and relevance to evaluating TTP programmes' impact. However, these questions require independent validation in a larger and systematic sample of relevant modeling studies which have appeared in later stages of the pandemic.

© 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Introduction

Decision-making related to the COVID-19 pandemic has made extensive use of information from studies using complex mathematical models. Specialist technical and contextual knowledge is necessary for detailed ‘critical appraisal’ of such studies. However, public health professionals lacking relevant technical knowledge are often required to evaluate quality and relevance of modelling studies.¹ It would be useful for non-specialists, especially public health professionals with only standard (i.e. MPH level) training in epidemiology, to be able to quickly assess when to bring new COVID-19 modeling papers (appearing in large numbers since the start of the pandemic) to the attention of modeling specialist colleagues.

* Corresponding author. 40 East Barnton Avenue, Edinburgh EH4 6AQ, UK. Tel: +44 0 7515198002.

E-mail addresses: john.frank@ed.ac.uk (J.W. Frank), glenn.marion@bioss.ac.uk (G. Marion), andrea.wilson@roslin.ed.ac.uk (A. Doeschl-Wilson).

Several authors^{2–6} have developed approaches to assess internal and external validity for modeling studies. However, these tools are generic and encompass a broad range of models, spanning clinical diagnostic/prognostic decision tools through to burden-of-illness estimates and cost-effectiveness analyses.

We address this gap by developing a “critical appraisal” tool, for non-specialists to efficiently screen COVID-19 modeling studies for quality and relevance to COVID-19 test trace and protect (TTP) programmes. TTP programmes test individuals, track or trace potential contacts of positive cases and then protect public health by providing advice regarding isolation or quarantine to both cases and contacts (We would cite Grantz et al.⁷ as providing a particularly clear and generalizable pictorial description of precisely how TTP programmes work.). Specifically, we devise a critical appraisal question checklist to address the question: “What are the key indicators of modeling study quality and relevance, for evaluation of TTP programme overall effectiveness in reducing COVID-19 transmission?”

Methods

Our objectives were to 1) identify the key modifiers affecting TTP programme effectiveness in reducing COVID-19 transmission; 2) generate less than ten easy-to-use critical appraisal (CA) questions that allow non-modelers, with only basic epidemiological training, to assess the quality and relevance of modelling studies for evaluating such effectiveness; and 3) demonstrate application of the proposed CA questions using purposively identified modelling studies.

We applied *Iterative Measurement Loop* methodology (see Tugwell et al.⁸), an established critical appraisal (CA) tool for analyzing the population-level effectiveness and efficiency of competing healthcare interventions, to evaluate TTP programme effectiveness in reducing COVID-19 transmission. This led to a comprehensive list of factors affecting TTP programme effectiveness, based on the ‘Healthcare Effectiveness Equation’ (see Box 1).⁸

We adopt the standard CA tool approach (see CASP and Oxford CEBM websites^{9,10}) of identifying a checklist of questions that, in sequence:

1. Screen out studies not directly relevant, i.e. determine whether the study in question addresses key aspects, identified through *Iterative Measurement Loop* methods⁸ that co-determine TTP programme overall effectiveness.
2. Assess *internal validity*, i.e. are study findings logically derived from the data presented and analysed?
3. Assess *external validity*, i.e. are the findings applicable to the reader’s particular decision-making situation? In this case, the evaluation of a specific COVID-19 TTP programme (e.g. as currently deployed in UK and most HICs.)

To generate specific CA questions, we performed a *purposive* review of modeling papers that assess TTP programme effectiveness, to identify *key shortcomings* with respect to the three criteria earlier. This was limited to studies of high-income countries (HICs),

and papers published (or listed on relevant pre-print archives) from early 2020 to May 1, 2021. The review was purposive, rather than systematic or narrative, in that modeling papers fitting the inclusion criteria were sampled until no further generic shortcomings were being identified – so-called ‘saturation.’¹¹ We were unable to validate against an independent sample of relevant TTP modelling papers, because we exhausted the most widely cited studies published during the study period in developing the CA questions. Such validation, in particular for low- to middle-income countries (LMICs), has therefore been left to other investigators, who will need to use a representative sample of suitable modelling papers published later in the pandemic.

Results

Critical appraisal question conceptual framework: How do COVID-19 TTP programmes work, and what are the key modifiers of their effectiveness?

Fig. 1 provides a schematic description of the rather complex string of processes involved in TTP programme implementation. These can be distinguished by direct effects (‘A’ in Fig. 1) associated with the positive-tested (index) case and by indirect effects (‘B’) associated with the contacts of that case. Box 1 shows the key modifiers of any TTP programme’s effectiveness that can potentially diminish its overall impact on COVID-19 transmission, as derived from the *Iterative Measurement Loop* associated with the factors in Fig. 1, based on the ‘Healthcare Effectiveness Equation’.⁸

Purposive literature search

The most relevant modelling studies for generating checklist questions were identified through targeted search in Google Scholar and widely used pre-print servers (e.g. bioRxiv, medRxiv), using the keywords ‘COVID* AND model* AND test* AND trace/tracing AND protect/quarantine/isolate AND effect,’ and by hand-




Fig. 1. Key Modifiers of TTP Programme Effectiveness. TTP, test trace and protect.

Text Box 1: Key Modifiers Affecting test trace and protect (TTP) Programmes' Overall Effectiveness**A. DIRECT EFFECTS ON SECONDARY CASES* FROM ISOLATING TEST-POSITIVE (INDEX) CASES.**

1. **TEST COVERAGE:** % of all transmitting cases obtaining a COVID-19 test result within the time window required for potential impact from TTP actions
2. **DIAGNOSTIC ACCURACY:** % of truly infectious cases correctly identified by testing = test sensitivity under real-world conditions (including swab technique), potentially varying by time since infection
3. **TEST and TRACE SUCCESS RATE:** % of positive-tested persons notified by TTP staff of test result/need to act (e.g. isolate)
4. **PROVIDER COMPLIANCE FOR CASES:** proportion of advice given to test-positive cases (e.g. re isolation) which is scientifically accurate
5. **TTP PROGRAMME DELAYS:** % of total infectiousness potential averted in those testing positive, considering all relevant delays
6. **COMPLIANCE WITH ISOLATION:** % of test-positive cases who comply with the isolation advice, prorated by degree of compliance and effectiveness of recommended isolation measured in terms of remaining % of total infectiousness potential averted

COMBINED WITH:

B. INDIRECT EFFECTS ON ONWARD TRANSMISSION BY CONTACTS OF INDEX (TEST-POSITIVE) CASES*: all the analogous factors affecting the effectiveness of interruption of further transmission by the contacts of the test-positive case:

1. **CONTACTS LISTING COMPLIANCE:** combining willingness and ability to name all relevant contacts since infectiousness began, including adequate identifiers for typical tracing success
2. **CONTACT TRACING RATE OF TTP**
3. **PROVIDER COMPLIANCE FOR CONTACTS:** proportion of advice given to contacts of test-positive cases (e.g. re-isolation) which is scientifically accurate
4. **CONTACTS' COMPLIANCE WITH QUARANTINE**
5. **CONTACT TRACING DELAYS:** delays in tracing the contacts of index cases could have highly non-linear effects. This is because rapid tracing could limit cascade of subsequent transmission along whole branches of the network of contacts of the case, their contacts etc., whereas delays make it more likely that such cascades are set in motion leading to exponential growth in case numbers.

* Both asymptomatic (including pre-symptomatic and symptomatic cases are meant by this term – see text under Question #2 in the Results section for commentary on this point).

Explanatory Note: Each of these steps should be assessed in terms of the accuracy with which each element in the process is modelled. Studies that make an effort to assess uncertainty are in general to be preferred over those that offer false certainty e.g. a range of rates of compliance or effectiveness of isolation advice offer a more realistic representation of the state of knowledge than point estimates.

Source: modified from Tugwell et al.⁸

Note: Based on original healthcare effectiveness models, multiplication of the aforementioned identified modifiers for cases and contacts, respectively, would yield a crude estimate for the overall actual programme effectiveness, comprising effects from actions involving: A. (index) cases; B. contacts of cases. If the probability of 'success,' in terms of percentage-correct-completion, for each of the six modifiers of overall programme effectiveness for test-positive cases is, say 50%, then the overall proportion of potential optimum impact on transmission by programme action involving such cases is: $[0.5 \times 0.5 \times 0.5 \times 0.5 \times 0.5 \times 0.5] = 1/64 = 1.6\%$ – i.e. the programme impact on transmission from actions taken regarding index cases is only 1.6% of the overall potential reduction in such transmission. At some points in the UK's national Test and Trace Programme, some of these modifiers are now thought to have had levels of success even lower than 50% (House of Parliament, 2021).

It should be noted however that the assumption of multiplicativity, representing independent probabilities for the effects of each of the diverse modifiers of effectiveness, is not necessarily warranted and may underestimate actual programme success, emphasizing the need for more sophisticated mathematical models.

searching the citations in those studies and published reviews of COVID-19 TTP effectiveness modelling (sometimes compared with other control measures). The range of identified issues regarding internal or external validity was fully captured by twelve original studies,^{7,11–22} published between early 2020 (effectively the first such studies after the pandemic began) and

May 2021. No additional issues compromising internal or external validity were identified from other modelling studies published during that the time period. As a result, the authors were able to identify six major sorts of shortcoming affecting such modeling, which were then integrated into the critical appraisal questions listed below.

Critical appraisal questions for screening modeling studies potentially relevant to COVID-19 TTP effectiveness evaluation

QUESTION #1. KEY MODIFIERS: Does the study incorporate or account for the effects, on COVID-19 transmission, of variation in the full set of key modifiers of overall TTP programme effectiveness identified in Text Box 1? (If not, stop here: study not likely to be useful)

It is important to note that a modeling study may not explicitly mention each individual modifier of effectiveness listed in Box 1, as it may 'bundle' several modifiers into one or more model parameters or process. For example, Grantz et al.⁷ bundled 'coverage' (effectiveness modifier #A1) and 'test diagnostic accuracy (i.e. sensitivity)' (#A2) with modifier #A6 'compliance with advice to isolate,' into a single parameter – 'isolation completeness' – representing the probability that an infection in the community is detected and isolated by a TTP programme. This also illustrates that studies may use different terminology for key modifiers. To enable assessment of internal and external validity definition and underlying assumptions for each modifier must be stated.

QUESTION #2. STRUCTURE AND SCALE: Are models used in the study employing a structure and scale appropriate for evaluating the impact on COVID-19 transmission of TTP programmes operating at the scale of interest, e.g. national or regional?

Identifying appropriate model structure and scale to assess COVID-19 TTP programme effectiveness is challenging, and the twelve studies identified were found to be heterogeneous in this respect. In terms of structure, for example one might expect strong dependence of model results on assumed between-individual contact patterns, but some models simply assume homogeneous mixing (e.g. Contreras et al.¹⁸). Similarly, accounting for asymptomatic or pre-symptomatic carriers of SARS-CoV-2^{23,24} affects testing coverage of potential transmitters (#A1 in Text Box), but only some in-scope studies do so (e.g. again, not Contreras et al.)¹⁸ Caution is advised when considering models that employ coarse scales or overly simplistic structures for contact patterns. Such models may only be able to provide useful predictions of a qualitative nature (e.g. relative importance of specific modifiers on overall predictions). Internal and external validity of model results should be carefully examined in relation to such scope and scale considerations.

For example, generalising from an early study of the local COVID-19 TTP programme (including a widely downloaded mobile phone app) on the Isle of Wight just off the southern English coast¹⁹ may be problematic; its small study population size, and perhaps even more so its unique geography, surely limit its applicability to large nation states.

QUESTION #3. PARAMETERISATION: Are key inputs (e.g. values for COVID-19's key transmission parameters and modifiers of effectiveness of TTP programmes, as listed in Box 1) credibly derived (i) using models fitted to representative data or (ii) from suitable peer-reviewed studies, and ideally systematic reviews and meta-analyses?

This criterion would probably have constituted an unreasonably high bar during the first year of the pandemic, where datasets were just starting to get assembled and modelers were unlikely to be granted full access to raw data. Furthermore, too few primary studies, and certainly systematic reviews of them, had been completed until very recently, with many key studies awaiting final peer-review available only through 'pre-print' archives, such as medRxiv. Even as late in the pandemic as the end of 2020, Quilty et al.²⁰ tally publications relevant to estimating quarantine-duration reduction, under rapid antigen testing, with 59 papers on PubMed and 1934 on medRxiv. However, it is now entirely reasonable to

demand critical inputs be derived from high-quality sources and analyses, ideally accounting for multiple sources, appropriately vetted for quality and statistically summarized where appropriate, such as two recent syntheses of incubation period data.^{25,26}

QUESTION #4. UNCERTAINTY QUANTIFICATION: Does the study account for a credible range of values for key input parameters, by executing comprehensive sensitivity analyses, showing resulting uncertainty, e.g. credible intervals or distributions, for key model outputs?

A key issue is the level of uncertainty associated with best estimates of key parameters. The fewer high-quality primary studies providing suitable data, and the narrower the range of relevant settings in which they were conducted, the more important a comprehensive sensitivity analysis becomes. Both Grantz et al.⁷ and Contreras et al.¹⁸ appear to meet this criterion, with sensitivity analyses across a wide range of input parameter values.

QUESTION #5. CONSISTENCY WITH OTHER STUDIES [EXTERNAL VALIDITY]: Are key results arising from the model(s) consistent with other high-quality evidence on impact and performance of TTP programmes?

Assessing external validity is not only a matter of looking explicitly for consistency of results across comparable studies and identifying outliers; it also involves noting entire categories of sub-studies (e.g. estimating key model inputs' distributions in particular settings – see above) where there is virtually no replication available. This a particular problem with COVID-19 research, simply because no study was possible until about February/March 2020. As a specific example of good practice in this regard, we would point to the work of the UK's Modeling Sub-Advisory Group (SPI-M) who have carefully issued consensus statements based on a variety of diverse modeling approaches.²⁷

QUESTION #6. SENSE CHECK (EXTERNAL VALIDITY): What specific questions/settings does the appraiser wish to address? Is the model being appraised credibly applicable to these (e.g. the UK in 2021)?

This final question provides the opportunity to ask "Do I have any remaining doubts (not covered above) about applicability of this study to the particular TTP programme I want to evaluate?" Potential sources of non-generalisability should be assessed along with issues related to the intended application. For example, the agent-based modelling study of Aleta et al.²² utilises detailed contact structures, based on pre-pandemic mobility data from Boston, USA, and models effects of applied COVID-19 interventions on these assumptions. This study may provide useful guidelines for developing comparable models; however, direct application to other countries is problematic because of likely differences in the pre-pandemic contact patterns and deployment of social distancing measures.

Discussion (and practical lessons learned)

Here we describe the lessons learned to guide those embarking on a literature (or systematic) review of modeling studies to inform evaluation of TTP programmes:

Relative timing of the modelling study to events. Particularly in the context of CA questions 2 (STRUCTURE AND SCALE) and 3 (PARAMETERISATION), it is important to consider the timing of the study in relation to data and knowledge available at the time of publication, compared to when the critical appraisal is conducted. For example, in early studies the proportion asymptomatic cases may be based on purely cross-sectional studies whereas, due latent period, only cohort studies provide a clear picture of the true percentage of cases which are fully asymptomatic.^{23,24} Models based on such early estimates of key parameters can therefore be expected to have a 'limited shelf life' and must be interpreted with caution.

Demographic context. Key parameters vary within and between settings. For example, the secondary attack rate within a household (or household attack rate) is likely to vary considerably within and across populations, but only some models explicitly account for such heterogeneity. Furthermore, households are not of consistent size, age–sex composition, and crowdedness across societies (let alone comparable with respect to cross-reactive immuno-competence arising from previous exposure to other coronaviruses.²⁸ Secondary attack rates based on household data will not be fully generalizable from one society – e.g. China, with low birth rates but many households which include older relatives,²⁹ to another – e.g. in sub-Saharan Africa, with high birth rates, a very young population overall, and many communities with extremely crowded housing, such as large low-income informal settlements.¹²

Geographical, cultural, or political features. A further caveat to external validity is that some input parameters may be contextualized by other important but often unstated local geographical, cultural, or political features. For example, isolated islands (either physically isolated, such as Iceland, New Zealand, and the Faroe Islands) or politically distinct ‘islands’ with historically strong border controls (such as Hong Kong, Singapore and Taiwan) have in some cases introduced strict COVID-19 control measures, including gradations of social distancing through to full ‘lock-down,’ while at the same time enforcing draconian inbound-traveler restrictions.¹⁴ The effect of such imported-case exclusion measures can be large¹⁵ and may influence observed impacts of TTP programmes because transmission is rendered entirely internal to the population in question. Such issues are most apparent in studies of closed ‘institutional/cruise-ship’ settings, such as the well-known Diamond Princess outbreak early in the pandemic.¹⁶ Such extreme settings may hold advantages for estimating key transmission parameters; however, such estimates may be confounded by atypical features, such as population-age profiles or saturation of air-circulation systems by aerosols, leading to more of a ‘point (or common) source’ epidemic curve, rather than a ‘person-to-person’ transmission curve.³⁰ Thus, generalizing from ‘island’ settings to societies with more porous borders should be undertaken with extreme caution.

Nuances of TTP programmes. TTP programmes may appear to be similar between jurisdictions, but in fact may be quite different in important respects. For example, TTP programmes with strong legal sanctions against cases or their contacts, who are non-compliant with advice to isolate/quarantine (including mandatory ‘quarantine hotel’ stays under armed guard), would be expected to achieve high rates of transmission interruption, compared to more voluntary programmes, relying entirely on ‘self-isolation at home.’¹⁷ There are many such features of TTP programmes that powerfully influence case and contact compliance with advice to isolate/quarantine (see Box 1), such as concerns about data security, and they may or may not be fully described in a given published account.

Shortcomings of modelling study reporting. We note, as have other commentators^{1–3} that inconsistent and often incomplete reporting was common among the dozen key modelling studies we examined in detail. Standard guidance for such reporting has been published and is constantly being refined.^{1,3}

Degree of compliance. When using models to evaluate any TTP programme, a key concern is how that programme is executed on the ground, as well as the full context of other societal behavioural patterns relevant to COVID-19 transmission e.g. compensatory behaviours, and the extent to which the study accounts for such factors, especially via proper reporting practices (see earlier discussion).

In summary, ‘the devil is in the details’. Anyone reviewing modeling studies which make use of model inputs from settings likely affected by these peculiarities should exercise extreme

caution in extrapolating the results to settings which are fundamentally different.

The major strength of this study is that it utilized a purposive sample of about a dozen highly cited early modeling studies of COVID-19 TTP programmes’ effectiveness to generate CA questions suitable for use by non-modelers, with only MPH-level training in epidemiology, for screening such studies for more detailed attention by trained modelers.

The major weakness of this study is that it did not attempt a systematic review of this exploding literature (as of spring 2021), but instead relied on the likely saturation of identifiable weaknesses, based on a purposive sample of early studies. This limitation may have resulted in bias and also limit the applicability of these CA questions to later modelling studies utilizing novel and improved methods and/or higher-quality input data. A second major weakness is that the authors did not attempt to validate the CA questions developed on an independent sample of modeling studies, simply because they had already used all the most highly cited studies of this kind in developing the questions. We leave that important task to others, now that many more pertinent modeling studies have been published.

This study has used a systematic process to develop a brief decision tool – involving creation of a bespoke conceptual framework, a purposive search to identify potential modelling study shortcomings, and the subsequent creation of six CA questions. The tool is intended to allow non-modelers to critically assess modelling studies that aim to address the impact on COVID-19 transmission of TTP programmes, a major global intervention to reduce viral transmission. Only by others’ attempts to use these questions can we learn how useful they are. To that end, we invite public health professionals who are involved in evidence reviews on this topic to write to us, in care of the corresponding author, about their experiences with this tool.

Author statements

Ethical approval

Not required; no human participants or their data were involved in this research.

Funding

None; this research did not receive any grant from sources in the public, commercial, or not-for-profit sectors.

Competing interests

None declared.

References

1. Egger M, Johnson L, Althaus C, Schöni A, Salanti G, Low N, et al. Developing WHO guidelines: time to formally include evidence from mathematical modelling studies. *F1000Research* 2017;**6**. <https://doi.org/10.12688/F1000RESEARCH.12367.2>.
2. Bennett C, Manuel DG. Reporting guidelines for modelling studies. *BMC Med Res Methodol* 2012;**12**:168. <https://doi.org/10.1186/1471-2288-12-168>. Published 2012 Nov 7.
3. Caro JJ, Eddy DM, Kan H, Patel B, Eldessouki R, Briggs AH, et al. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC good practice task force report. *Value Health* 2014;**17**(2):174–82. <https://doi.org/10.1016/j.jval.2014.01.003>.
4. Holmdahl I, Buckee C. Wrong but useful — what COVID-19 epidemiologic models can and cannot tell us. *N Engl J Med* 2020;**383**(4):303–5. <https://doi.org/10.1056/nejmp2016822>.
5. Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA, et al. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—an overview in the context of health decision-making. *J Clin Epidemiol* 2021;**129**:138–50. <https://doi.org/10.1016/j.jclinepi.2020.09.018>.

6. Zawadzki RS, Gong CL, Cho SK, Zawadzki NK, Hay JW, Drabo EF, et al. Where do we go from here? A framework for using Susceptible-Infectious-Recovered Models for policy making in emerging infectious diseases. *Value Health* 2021;**24**(7):917. <https://doi.org/10.1016/j.jval.2021.03.005>.
7. Grantz KH, Lee EC, D'Agostino McGowan L, Lee KH, Metcalf CJ, Gurley ES, et al. Maximizing and evaluating the impact of test-trace-isolate programs: a modeling study. *PLoS Med* 2021 Apr 30;**18**(4):e1003585.
8. Tugwell P, Bennett KJ, Sackett DL, Haynes RB. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. *J Chron Dis* 1985 Jan 1;**38**(4):339–51.
9. *Critical appraisal skills programme*. <https://casp-uk.net/>. [Accessed 22 February 2021].
10. *Oxford centre for evidence-based medicine*. <https://www.cebm.net>. [Accessed 22 February 2021].
11. Gentles SJ, Charles C, Ploeg J, McKibbin KA. Sampling in qualitative research: insights from an overview of the methods literature. *Qual Rep* 2015 Apr 26;**20**(11):1772–89.
12. Van Zandvoort K, Jarvis CI, Pearson CA, Davies NG, Ratnayake R, Russell TW, et al. Response strategies for COVID-19 epidemics in African settings: a mathematical modelling study. *BMC Med* 2020 Dec;**18**(1):1–9.
13. Kretzschmar ME, Rozhnova G, Bootsma MC, van Boven M, van de Wijkstra JH, Bonten MJ. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. *Lancet Pub Health* 2020 Aug 1;**5**(8):e452–9.
14. Strøm M, Kristiansen MF, Christiansen DH, Weihe P, Petersen MS. Elimination of COVID-19 in the Faroe Islands: effectiveness of massive testing and intensive case and contact tracing. *Lancet Region Health-Eur* 2020 December 26. <https://doi.org/10.1016/j.lanpe.2020.100011>. 2020.
15. Russell TW, Wu JT, Clifford S, Edmunds WJ, Kucharski AJ, Jit M. Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study. *Lancet Pub Health* 2021 Jan 1;**6**(1):e12–20.
16. Mizumoto K, Chowell G. Transmission potential of the novel coronavirus (COVID-19) onboard the Diamond princess cruises ship, 2020. *Infect Dis Model* 2020 Jan 1;**5**:264–70.
17. Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. *Cochrane Database Syst Rev* 2020;(9):CD013574. <https://doi.org/10.1002/14651858.CD013574.pub2>.
18. Contreras S, Dehning J, Loidolt M, Zierenberg J, Spitzner FP, Urrea-Quintero JH, et al. The challenges of containing SARS-CoV-2 via test-trace-and-isolate. *Nat Commun* 2021 Jan 15;**12**(1):1–3.
19. Kendall M, Milsom L, Abeler-Dörner L, Wymant C, Ferretti L, Briers M, et al. Epidemiological changes on the Isle of Wight after the launch of the NHS Test and Trace programme: a preliminary analysis. *Lancet Digit Health* 2020 Dec 1;**2**(12):e658–66.
20. Quilty BJ, Clifford S, Hellewell J, Russell TW, Kucharski AJ, Flasche S, et al. Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study. *Lancet Pub Health* 2021 Mar 1;**6**(3):e175–83.
21. Kucharski AJ, Klepac P, Conlan AJ, Kissler SM, Tang ML, Fry H, et al. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. *Lancet Infect Dis* 2020 Oct 1;**20**(10):1151–60.
22. Aleta A, Martin-Corral D, Piontti AP, Ajelli M, Litvinova M, Chinazzi M, et al. Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. *Nat Human Behav* 2020 Sep;**4**(9):964–71.
23. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. *Off J Assoc Med Microbiol Infect Dis Canada* 2020 Dec;**5**(4):223–34.
24. Pollock AM, Lancaster J. Asymptomatic transmission of COVID-19. *BMJ* 2020;**371**:m4851.
25. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Ann Intern Med* 2020 May 5;**172**(9):577–82.
26. McAloon C, Collins Á, Hunt K, Barber A, Byrne AW, Butler F, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. *BMJ Open* 2020;**10**:e039652.
27. Anderson R, Donnelly C, Hollingsworth D, Keeling M, Vegvari C, Baggaley R. *Reproduction number (R0) and growth rate (R) of the COVID-19 epidemic in the UK: methods of estimation, data sources, causes of heterogeneity, and use as a guide in policy formulation*. Royal Society Rapid Review; August 24, 2020. <https://royalsociety.org/-/media/policy/projects/set-c/set-COVID-19-R-estimates.pdf>. [Accessed 31 March 2021].
28. Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. *Int J Infect Dis* 2021 Jan 1;**102**:577–83.
29. Wilder B, Charpignon M, Killian JA, Ou HC, Mate A, Jabbari S, et al. Modeling between-population variation in COVID-19 dynamics in Hubei, Lombardy, and New York city. *Proc Natl Acad Sci Unit States Am* 2020 Oct 13;**117**(41):25904–10.
30. Giesecke J. *Modern infectious disease epidemiology*. London: CRC Press; 2017.